Announcement of distribution agreement coincides with appearance of both
companies at Arab Health 2022, the largest medical equipment exhibition in the Middle East

VANCOUVER, BC, Jan. 27, 2022 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) today announced that it has signed a distribution agreement with Dubai-based medical technology company Emitac Healthcare Solutions (“Emitac”). Under the terms of the agreement, Emitac has become an official distributor of CognICA, Cognetivity’s medical device product, in the Middle East region.

Emitac is a leading healthcare innovator and solutions provider in the Middle East, with over 45 years of experience in the healthcare industry. It boasts an impressive array of public- and private-sector organisations among its customers and clients, from Dubai Healthcare City and the United Arab Emirates Ministry of Health & Prevention to Cleveland Clinic, Samsung Ultrasound Systems and Philips Healthcare.

CognICA is Cognetivity’s flagship medical device product. It is a cutting-edge, computerized test of cognitive function that offers numerous advantages over traditional pen-and-paper examinations, such as its short testing duration and high classification accuracy, coupled with the absence of a learning effect or any cultural or educational bias.

CognICA is FDA-registered and CE-marked, and has already been commercially deployed across three continents, including within the UK’s National Health Service (NHS) and in the state-of-the-art Clemenceau Medical Center in Dubai. The new agreement grants Cognetivity access to Emitac’s wealth of experience and connections in the Middle East, as well as the full range of its customer support services, in order to bolster CognICA’s already-impressive commercial rollout in the region.

News of the partnership coincides with the appearance of both companies at Arab Health 2022. Taking place in Dubai from 24 to 27 January, Arab Health is the largest medical equipment exhibition in the Middle East, with exhibitors from over 60 countries participating and more than 56,000 healthcare professionals due to attend.

Cognetivity’s attendance at Arab Health and the burgeoning commercial rollout of CognICA across the Middle East come at a salient moment for the region. According to a study published this year in The Lancet Public Health, the UAE and other Gulf countries will experience the highest increases worldwide in the number of people living with dementia by 2050. This represents a major impending healthcare challenge, which cutting-edge technology such as Cognetivity’s will play a vital part in tackling.

Dr Sina Habibi, CEO of Cognetivity, said: “We’re delighted to have established this partnership with Emitac Healthcare Solutions. As its list of existing customers and clients shows, Emitac is a hugely-respected name in the region, bringing the experience and the manpower required to service our clientele and reassure customers of our commitment in this market.”

“Dementia poses a serious and widespread threat to the ageing population of the Middle East,” he added. “In order to stop dementia from turning into a healthcare crisis, we need to be bold and act fast. I am confident that this new agreement is the best way to accelerate our ongoing commercial rollout in the region and thoroughly excited about the positive impact it will have on patients’ lives.”

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The ICA is currently available for clinical use in the USA, UK and Europe, with regulatory approval for other regions planned for 2022.

ON BEHALF OF THE BOARD
“Sina Habibi”
Sina Habibi
Chief Executive Officer and Director

FORWARD-LOOKING STATEMENTS:

Certain statements included in this news release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “assume” “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Cognetivity Neurosciences Ltd

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.